TRVI on Nasdaq

Trevi Therapeutics, Inc.

American pharmaceutical preparations company based in New Haven. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with another stock.

  • TickerTRVI on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersNew Haven, Connecticut1
  • Incorporated inDE2
  • Business address195 Church Street, 16Th Floor, New Haven, Ct 065102
  • Filer categoryNon-accelerated filer, Smaller reporting company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

We are a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income456789-$49.3M in 2025+85% since 2019
-$60.0M-$40.0M-$20.0M02019: -$26.6M-$26.6M20192020: -$32.5M-$32.5M2020+22%2021: -$32.5M-$32.5M2021−0%2022: -$29.9M-$29.9M2022−8%2023: -$33.9M-$33.9M2023+13%2024: -$51.5M-$51.5M2024+52%2025: -$49.3M-$49.3M2025−4%
Net income456789-$42.8M in 2025+64% since 2019
-$60.0M-$40.0M-$20.0M02019: -$26.1M-$26.1M20192020: -$32.8M-$32.8M2020+26%2021: -$33.9M-$33.9M2021+4%2022: -$29.2M-$29.2M2022−14%2023: -$29.1M-$29.1M2023−0%2024: -$47.9M-$47.9M2024+65%2025: -$42.8M-$42.8M2025−11%

Every line of the income statement as filed: the last 2 fiscal years, latest first.9

Period ending2025-12-312024-12-31
Research and development$33.5M$39.4M
General and administrative$15.8M$12.1M
Total operating expenses$49.3M$51.5M
Loss from operations-$49.3M-$51.5M
Interest income, net$6.5M$3.6M
Other expense, net-$31.0K-$15.0K
Interest expense$0-$4.0K
Total other income, net$6.5M$3.6M
Loss before income taxes-$42.8M-$47.9M
Income tax benefit-$64.0K-$30.0K
Net loss-$42.8M-$47.9M
Basic net loss per common share outstanding-$0.32-$0.47
Diluted net loss per common share outstanding-$0.32-$0.47
Weighted average common shares used in net loss per share attributable to common stockholders, basic134.7M shares102.0M shares
Weighted average common shares used in net loss per share attributable to common stockholders, diluted134.7M shares102.0M shares
Net unrealized gains on available-for-sale marketable securities$87.0K$90.0K
Comprehensive loss-$42.7M-$47.8M

Compare Trevi Therapeutics, Inc. with another company

Leadership

Who has led Trevi Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Jennifer L. Good2019–now

President

  1. Jennifer L. Good2019–now

Chief financial officer

  1. Christopher Seiter2019–2021
  2. Lisa Delfini2021–2026
  3. David C. Hastings2026–now
20202025
Board members and other officers (20)

Timeline

  1. Jun 5, 2019New chief executive Jennifer L. Good becomes CEO12

Filings

335 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 53 major events, 142 insider forms, 54 large holders, 3 private raises, 63 other. The latest 20:

  1. Sep 17, 20264 EDGAR
  2. Sep 15, 2026144 EDGAR
  3. Aug 6, 2026S-8 EDGAR
  4. Aug 6, 202610-Q EDGAR
  5. Aug 6, 20268-K EDGAR
  6. Aug 6, 2026SCHEDULE 13G/A EDGAR
  7. Jun 4, 20264 EDGAR
  8. Jun 4, 20264 EDGAR
  9. Jun 4, 20264 EDGAR
  10. Jun 4, 20264 EDGAR
  11. Jun 4, 20264 EDGAR
  12. Jun 4, 20268-K EDGAR
  13. May 7, 2026SCHEDULE 13D/A EDGAR
  14. May 6, 2026SCHEDULE 13G/A EDGAR
  15. May 5, 202610-Q EDGAR
  16. May 5, 20268-K EDGAR
  17. Apr 21, 2026DEF 14A EDGAR
  18. Apr 21, 2026ARS EDGAR
  19. Apr 21, 2026DEFA14A EDGAR
  20. Apr 17, 2026424B5 EDGAR

The 335 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

52 open-market trades by officers, directors and large owners since October 2021: 18 buys and 34 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 15, 2026Heffernan Michael ThomasDirectorSale39,473$15.09$595.8KForm 4
Mar 25, 2025SCIASCIA THOMASChief Scientific OfficerSale2,631$6.60$17.4KForm 4
Mar 21, 2025GOOD JENNIFER LPresident & CEOSale5,263$6.58$34.6KForm 4
Mar 10, 2025Simon FarrellChief Commercial OfficerSale81,313$6.75$549.1KForm 4
Sep 9, 2024GOOD JENNIFER LPresident & CEOSale1,840$3.04$5.6KForm 4
Sep 6, 2024GOOD JENNIFER LPresident & CEOSale4,219$3.03$12.8KForm 4
Sep 5, 2024GOOD JENNIFER LPresident & CEOSale40,277$3.11$125.3KForm 4
Sep 4, 2024GOOD JENNIFER LPresident & CEOSale10,981$3.02$33.2KForm 4
Sep 3, 2024GOOD JENNIFER LPresident & CEOSale3,863$3.02$11.7KForm 4
Aug 27, 2024Meeker David PDirectorSale4,555$2.93$13.3KForm 4
Aug 19, 2024SCIASCIA THOMASChief Scientific OfficerSale16,496$2.96$48.8KForm 4
Aug 16, 2024SCIASCIA THOMASChief Scientific OfficerSale18,660$2.76$51.5KForm 4
Aug 15, 2024SCIASCIA THOMASChief Scientific OfficerSale12,745$2.79$35.6KForm 4
Aug 14, 2024SCIASCIA THOMASChief Scientific OfficerSale100$2.75$275Form 4
May 29, 2024SCIASCIA THOMASChief Scientific OfficerSale53,368$2.55$136.1KForm 4
May 22, 2024Delfini LisaChief Financial OfficerSale4,350$2.64$11.5KForm 4
May 20, 2024GOOD JENNIFER LPresident & CEOSale25,037$2.86$71.6KForm 4
May 10, 2024GOOD JENNIFER LPresident & CEOSale4,578$2.90$13.3KForm 4
Oct 11, 2023Delfini LisaChief Financial OfficerSale785$2.02$1.6KForm 4
Sep 11, 2023Delfini LisaChief Financial OfficerSale711$2.20$1.6KForm 4

All 52 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Apr 11, 2022Raised $55 million in a private offering of equity Form D: 12 investors so far Form D
  2. Oct 18, 2021Raised $3 million in a private offering of equity Form D: 1 investor so far Form D
  3. Oct 5, 2021Raised $11.8 million in a private offering of equity Form D: 1 investor so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
NEA Management Company, LLC13,222,228$246.6M15.5%No change
Fmr LLC12,562,839$234.3M0.0%+4,524,778
BlackRock, Inc.11,155,026$208.0M0.0%+914,840
Frazier Life Sciences Management, L.P.9,939,447$185.4M4.0%−100
Wellington Management Group Llp5,684,592$106.0M0.0%+495,504
Vanguard Capital Management LLC5,530,675$103.1M0.0%+552,108
Vivo Capital, LLC5,094,668$95.0M8.7%No change
Woodline Partners LP4,081,333$76.1M0.2%+3,080,551
Vestal Point Capital, LP3,100,000$57.8M1.4%+933,496
Mpm Bioimpact LLC3,073,577$57.3M3.5%−224,853
Frontier Capital Management Co LLC3,070,740$57.3M0.5%+1,076,448
Assenagon Asset Management S.A.3,050,628$56.9M0.0%New
State Street Corp3,027,315$56.5M0.0%+362,002
Geode Capital Management, LLC2,928,068$54.6M0.0%+149,837
Marshall Wace, Llp2,674,137$49.9M0.0%−1,291,882
Eventide Asset Management, LLC2,660,000$49.6M0.7%+37,694
Rubric Capital Management LP2,504,513$46.7M0.4%−1,207,860
Artia Global Partners LP2,210,852$41.2M7.8%+197,250
Acorn Capital Advisors, LLC2,144,844$40.0M10.9%No change
First Light Asset Management, LLC2,097,215$39.1M2.4%New
Pictet Asset Management Holding SA2,013,786$37.6M0.0%+307,738
Logos Global Management LP1,880,000$35.1M1.5%−520,000
Affinity Asset Advisors, LLC1,800,172$33.6M1.7%−200,000
Emerald Advisers, LLC1,797,611$33.5M0.8%−41,955
Siren, L.L.C.1,786,867$33.3M0.7%No change

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49